FitLife Brands, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2014, with comparative 2013 results. FitLife Brands develops and distributes nutritional supplements under the NDS, PMD, Siren Labs, and CoreActive brands, primarily through GNC franchise locations in the United States and internationally. The company marketed more than 60 products to approximately 900 domestic and 300 international GNC franchise locations.
Financial Performance and Position
| Metric | 2014 | 2013 | Change |
|---|---|---|---|
| Revenue | $19,960,376 | $19,684,030 | +1.4% |
| Gross profit | $7,092,910 | $7,135,393 | -0.6% |
| Gross margin | 35.5% | 36.2% | Down approximately 70 basis points |
| Operating income | $1,852,125 | $1,387,552 | +33.5% |
| Operating margin | 9.3% | 7.1% | Improved |
| Net income | $1,673,602 | $1,292,425 | +29.5% |
| Net margin | 8.4% | 6.6% | Improved |
| Basic EPS | $0.20 | $0.17 | Increased |
| Diluted EPS | $0.20 | $0.14 | Increased |
| Cash from operating activities | $1,506,426 | $2,564,740 | Down 41.3% |
| Cash and cash equivalents | $4,353,699 | $3,305,179 | +31.7% |
| Total assets | $10,103,970 | $9,230,303 | +9.5% |
| Stockholders’ equity | $6,713,714 | $4,808,598 | +39.6% |
Cost of goods sold increased 2.5% to $12.9 million. General and administrative expense declined $464,000 to $2.6 million, while selling and marketing expense declined modestly to $2.4 million. Interest expense increased to $94,667 from $40,906. Other income included a $137,500 gain associated with the Kaniwa intellectual property transaction, partially offset by a $50,000 write-off of the company’s YogaEarth investment.
Working capital increased to $7,109,990 from $5,659,176. Accounts receivable increased to $1,685,623, principally because of the transition to GNC’s centralized distribution platform. Inventory declined to $2,284,922 from $2,752,636.
Debt and Liquidity
Total notes payable were $2,383,919 at December 31, 2014, consisting of a $437,089 revolving line of credit and a $1,946,830 term loan. The line of credit bears interest at 3.0% plus one-month LIBOR and was scheduled to mature May 15, 2015. The term loan bears fixed interest of 3.6%, amortizes monthly, and matures August 15, 2018. Current debt obligations totaled $944,120, and long-term debt totaled $1,439,799.
The company generated positive operating cash flow but used $504,490 in financing activities, primarily for term-loan principal repayments. Management stated that cash from operations and existing cash resources were expected to fund liquidity needs for the next 12 months and the remainder of 2015. The filing cautions that additional working capital would be required if positive operating cash flow is not maintained.
Material Changes and Business Developments
- On May 1, 2014, most product distribution transitioned to GNC’s centralized distribution platform; protein products transitioned in mid-September. This altered the presentation of distribution-related economics between revenue and cost of goods sold and affected year-over-year comparability.
- Approximately 50% of 2014 sales were direct sales to GNC franchise locations, and approximately 48% were sales to GNC for indirect distribution. The company therefore remains highly dependent on GNC-related demand.
- The company introduced 27 products in 2014, including eight new products, 16 reformulations, and three flavor extensions.
- On June 30, 2014, the board authorized a share repurchase program of up to $600,000 annually, subject to a $50,000 monthly limit. No repurchases occurred during the fourth quarter of 2014. By March 12, 2015, the company had repurchased 120,354 shares at an average price of $2.15 per share.
- The company issued 81,042 common shares during 2014, primarily for employee, director, and settlement-related purposes, and issued 40,000 employee stock options.
- The company wrote off its remaining $50,000 YogaEarth investment and obtained 100% ownership of Kaniwa protein extraction intellectual property through a settlement involving $84,500 of company stock and a recorded $137,500 gain. The USPTO did not allow the company’s claims in December 2014; the company intended to respond by March 23, 2015.
Outlook, Risks, and Unusual Items
Management expected continued growth through additional domestic and international GNC franchise locations, broader distribution of CoreActive products, and expansion into GNC corporate stores. The company anticipated launching the Metis Nutrition brand in the first half of 2015, with products expected on shelves during the second quarter. Management described Metis as a potential long-term growth platform but acknowledged execution and market-acceptance risks.
- GNC-related sales represented approximately 98% of total 2014 revenue, creating significant customer and channel concentration risk.
- The company relies on a limited number of third-party manufacturers and suppliers. Disruptions, quality failures, contamination, recalls, or inability to obtain replacement sources could materially reduce sales.
- The business is subject to extensive FDA, FTC, state, international, labeling, advertising, and product-claim regulation. Noncompliance could result in penalties, injunctions, recalls, litigation, or loss of market access.
- The company faces substantial competition from larger and better-capitalized supplement companies and online sellers.
- A September 2014 California Proposition 65 notice alleged labeling violations; the company stated that potential exposure could not reasonably be estimated and intended to defend the matter.
- A December 2014 federal lawsuit alleged misleading claims concerning Testofen-containing products. NDS used Testofen in a limited number of products and stated that it intended to vigorously defend the allegations.
- The company has federal net operating loss carryforwards of approximately $19.4 million, potentially usable through 2032, but utilization may be limited under Section 382 and other rules. A $689,000 deferred tax asset remained recorded at year-end.
- The filing states that the company has achieved profitability but may not sustain it. It also identifies dependence on key personnel, product liability, limited stock liquidity, OTC market volatility, and potential penny-stock restrictions as material risks.
Investor Verification Checklist
- Verify the sustainability of 2014 profitability and whether operating cash flow improves after the GNC distribution transition.
- Assess GNC concentration, franchisee purchasing behavior, and the economics of centralized versus direct distribution.
- Confirm repayment, renewal, or refinancing arrangements for the revolving line of credit scheduled to mature in May 2015.
- Review the progress, costs, and commercial results of the Metis Nutrition launch and expansion into GNC corporate stores.
- Monitor the Proposition 65 notice, Testofen litigation, and any related reserves, settlements, or adverse developments.
- Evaluate the status and commercial value of the Kaniwa intellectual property after the USPTO’s non-allowance notice.
- Reconcile the share repurchase activity disclosed through March 2015 with year-end shares outstanding and subsequent dilution from options or warrants.
- Review the audited financial statements and notes for the unusual YogaEarth write-off, Kaniwa gain, deferred tax asset, debt maturities, and customer concentration.